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Abstract
Background: The association between lobular breast cancer and family history is not clear. The aim of the study
was to possibly identifying new hereditary patterns predisposing for cancer in the different histopathologic
subtypes of breast cancer, with focus on patients with lobular breast cancer and cancer in their first degree
relatives.
Methods: In 1676 consecutive breast cancer patients detailed family history of cancer was related to
histopathologic subtype of breast cancer.
Results: Patients with lobular breast cancer were found to be significantly positively associated with having a
father diagnosed with cancer, OR 2.17 (95% confidence interval (CI) 1.37-3.46). The finding persisted after excluding
breast cancer in the family. Ductal breast cancer was associated with having a mother diagnosed with cancer.
There was a significant association between lobular breast cancer and having a father with prostate cancer, OR 2.4
(CI 1.1-5.3). The occurrence of having a father with prostate cancer for lobular breast cancer patients was higher in
the younger patient group, OR 2.9 (CI 1.1-7.8), and was still high but lost statistical significance in the older patient
group, OR 1.9 (CI 0.5-7.4). The association between lobular breast cancer and a father remained significant after
excluding fathers with prostate cancer, OR 1.94 (CI 1.20-3.14). Other commonly occurring tumor types in the father
included sarcoma and leukemia.
Conclusion: We propose that lobular breast cancer is associated with having a father diagnosed with cancer, most
commonly prostate carcinoma. Since the association remained after excluding family history of breast cancer, the
association seems independent of classical breast cancer heredity. The association with a father diagnosed with
cancer also remained after removing prostate cancer, indicating an independence from prostate cancer as well.
The reason for this association is genetically unclear, but could involve sex-specific imprinting.
Background
Risk factors, both genetic and environmental differ
between the histopathological subtypes of breast cancer,
one example is parity. It has been shown that increased
parity reduced the risk for all subtypes with the excep-
tion of medullary breast cancer [1]. Another risk factor,
ever-use of HRT is associated with an increased risk of
lobular breast cancer [2]. In hereditary breast cancer,
patients with BRCA1 [3]-associated breast cancer are
often hormone receptor negative and is more often of
the medullary type, whereas patients with BRCA2 [4]-
associated breast cancer have a mixture of receptor
negative and positive tumors and histopathologies [5].
The aim of the study was to further investigate the rela-
tionship between patients with different histopathological
subtypes of breast cancer and cancer in their first degree
relatives to possibly identify new hereditary patterns pre-
disposing for cancer. We focused our study on lobular
breast cancer since it is the second most common speci-
fied breast cancer subtype and not as well studied as duc-
tal breast cancer. Many studies tend to focus more on
molecular groups and as a supplement to them we
focused our study on the classical histopathologic sub-
types as a base for our study. Lobular breast cancer is the
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cancer usually comprising between 5-15% of all cases
[6-8]. Previous associations between lobular breast cancer
and family history of cancer have been found, especially
an association to family history of breast cancer in first
degree relatives [9-12]. The familial association of lobular
breast cancer could mainly be due to patients with
BRCA2 mutation or the occurrence of hereditary diffuse
gastric cancer [13]. However, there is a need for further
studies of familial cancer patterns in lobular breast can-
cer, comparing different histopathological types or mole-
cular subtypes.
Methods
The 1676 breast cancer patients included in this study
were all patients seen by one physician between 1
st of
January in 1980 and 1
st of January in 2009. Using a stan-
dardized questionnaire filled out by the physician, infor-
mation regarding previous family history of cancer was
obtained, as well as reproductive and hormonal factors.
The additional information concerning date of diagnosis,
histopathological subtype, tumor biologic factors (includ-
ing estrogen receptor (ER) and progesterone receptor
(PR) status) was collected from pathological reports and
hospital records. Pathological slides were not reexamined,
but the diagnosis determining treatment was used.
Recurrence of cancer, death and confirmation of the
diagnosis on the relatives was retrieved from the Regional
Cancer registry and census registry, and information
regarding germline mutations was obtained from the
Oncogenetic high-risk registry. Follow up was performed
until 1
st of January 2009. Informed consent was obtained
from all patients. Ethical approvals for this study were
obtained by the Ethical review board at Lund University,
reference nr: 110/92 and 108/93.
All statistical analyses were performed using SPSS
©
17.0. Only pure histopathological subtypes were used.
Mixed, rare types and those breast cancer cases where
the histopathological subtype was only known to be ade-
nocarcinoma were grouped as “Others” a n du s e da sa
reference group. Known mutation carriers were excluded
from all analyses (n = 19). For all analyses, two-sided p-
values ≤ 0.05 was considered statistically significant.
Odds Ratios (OR) were estimated with 95% confidence
intervals (CI). Because of the exploratory nature of this
study no adjustment for multiple testing was made, and
all results need to be validated in a different material.
Power analysis was made for ductal and lobular breast
cancer. Actual sample size was used for each calculation.
The significance level was set to 0.05, and the power to
0.80. For father with cancer the smallest detectable OR
for ductal breast cancer was 2.016, and lobular breast
cancer 3.436. For mother with cancer the smallest detect-
able OR for ductal breast cancer was 1.774, and lobular
breast cancer it was 3.213. Excluding cases with breast
cancer, the smallest detectable OR for ductal breast can-
cer was 2.176, and for lobular breast cancer 4.629.
Each histopathological tumor type was studied sepa-
rately in a logistic regression model in relation to the
occurrence of cancer in fathers, mothers, brothers and
sisters (y/n), no family history of breast cancer, horizontal
and vertical family history of breast cancer (y/n), ever-use
of HRT (y/n), number of children (linear) and age at
diagnosis (linear). A second analysis was performed in a
similar manner, but excluding cases with a family history
of breast cancer.
In a separate regression model histologic subtype of
breast cancer was related to having a father diagnosed
with cancer (y/n), ER-positivity (y/n), PR-positivity (y/n),
horizontal and vertical family history of breast cancer
(y/n) and age at diagnosis (linear). An analysis similar to
this was performed where cases with a family history of
breast cancer was excluded.
A third logistic regression model was used in which
lobular breast cancer was related to first degree relatives
with cancer (y/n), both including and excluding cases
with breast cancer diagnoses in mothers and sisters.
I nt h el a s tl o g i s t i cr e g r e s s i o nm o d e lh a v i n gaf a t h e r
with prostate cancer was related to ductal and lobular
breast cancer (y/n) and age at diagnosis (y/n) in three
variants; including all in the first, only patients younger
the 60 years of age in the second, and patients equal to
or older than 60 years of age in the third model. In a
fourth model prostate cancer in father was excluded.
Binomial tests were performed by using the number of
individuals in each branch of the family and comparing
males with cancer to females with cancer.
Results
The clinical series of 1676 breast cancer patients consisted
of 41% invasive ductal carcinoma, 8% invasive of lobular
carcinoma, 2% of medullary carcinoma and 1% of muci-
nous carcinoma. Others included mixed, rare types and
those breast cancer cases where the histopathological sub-
type was only known to be adenocarcinoma constituted
48%. The overall median age at diagnosis was 56 years old,
range 23-89. In the material, 931 patients were diagnosed
with tumors of one single invasive histological type, 63
with non-invasive, 545 with mixed tumor types and 137 of
the patients had tumors that were classified as unspecified
adenocarcinoma. At time of diagnosis, 257 (15%) of the
breast cancer patients had a father diagnosed with cancer
and 357 (21%) had a mother diagnosed with cancer. When
removing breast cancer in mothers, 219 (13%) patients had
mothers diagnosed with other cancers. Patients with tubu-
lar breast cancer had an increased number of sisters with
cancer (21%) [14], whereas lobular breast cancer patients
had an increased number of fathers diagnosed with cancer.
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tubular and lobular breast cancer, and least common
among patients with mucinous breast cancer (Table 1).
Associations between lobular breast cancer and having
a father diagnosed with cancer, OR 1.76 (CI 1.17-2.63),
and between ductal breast cancer and having a mother
with cancer, OR 1.13 (CI 1.01-1.65), were found. Among
tubular breast cancer patients it was less common to
have a mother diagnosed with cancer; OR 0.41 (CI 0.16-
1.08). Removing cases with breast cancer diagnoses in
mothers did not significantly alter the results, and the
association between having a father diagnosed with can-
cer and lobular breast cancer remained, OR 1.77 (CI
1.18-2.65) (Table 2).
Including ER- and PR-status did not alter the results
significantly, the association between lobular breast can-
cer and having a father diagnosed with cancer remained,
OR 2.17 (CI 1.37-3.46). Similar to the other analyses
removing cases with family history of breast cancer did
not alter the results significantly. Neither of the other his-
topathologic subtypes of breast cancer was associated to
a father diagnosed with cancer (Table 3). The association
between lobular breast cancer and a father diagnosed
with cancer remained after adding all first degree rela-
tives to the analysis. Exclusion of breast cancer in
mothers and sisters resulted in no apparent change of the
results. There was no case of a lobular breast cancer
patient with a child diagnosed with cancer (Table 4).
Table 1 Description of the population based patient material
All Ductal Lobular Tubular Medullary Mucinous Other
Age at diagnosis: median(range) 56 (23-89) 58 (24-89) 60 (30-84) 55 (35-79) 52 (31-77) 59 (36-79) 55 (23-87)
N (%) N (%) N (%) N (%) N (%) N (%) N (%)
Number of cases: 1676 695 (41) 141 (8) 43 (3) 27 (2) 25 (1) 745 (44)
Age at diagnosis:
20-39 147 (9) 57 (8) 7 (5) 4 (9) 4 (15) 2 (8) 73 (10)
40-59 848 (51) 336 (48) 62 (44) 23 (53) 13 (48) 10 (40) 404 (54)
60-69 422 (25) 175 (25) 49 (35) 12 (28) 6 (22) 8 (32) 172 (23)
70-89 258 (15) 127 (18) 23 (16) 4 (9) 4 (15) 5 (20) 95 (13)
Cancer in 1° relatives:
No family history of cancer 700 (42) 279 (40) 52 (37) 19 (44) 13 (48) 12 (48) 325 (44)
Child 20 (1) 13 (2) 0 (0) 1 (2) 0 (0) 0 (0) 8 (1)
Brother 83 (5) 47 (7) 10 (7) 0 (0) 0 (0) 3 (12) 23 (3)
Sister:
-all diagnoses 213 (13) 88 (13) 23 (16) 9 (21) 4 (15) 2 (8) 87 (12)
-not including bc 115 (7) 49 (7) 10 (7) 3 (7) 3 (11) 1 (4) 49 (7)
Father: 257 (15) 121 (17) 38 (27) 7 (16) 2 (7) 4 (16) 151 0)
- Prostate 67 (4) 28 (4) 8 (6) 2 (5) 1 (4) 2 (8) 26 (3)
Mother:
- all diagnoses 357 (21) 178 (26) 34 (24) 5 (12) 3 (11) 5 (20) 152 (20)
- not including bc 219 (13) 116 (17) 19 (13) 4 (9) 3 (11) 1 (4) 92 (12)
Unknown family history 13 (1) 8 (1) 1 (1) 0 (0) 0 (0) 0 (0) 4 (1)
Family history of bc:
No family history of bc 1131 (67) 465 (67) 93 (66) 28 (65) 20 (74) 18 (72) 507 (68)
Vertical family history 381 (23) 162 (23) 30 (21) 8 (19) 5 (19) 5 (20) 171 (23)
Horizontal family history 84 (5) 33 (5) 11 (8) 7 (16) 0 (0) 1 (4) 32 (4)
Cousin family history 67 (4) 27 (4) 6 (4) 0 (0) 2 (7) 1 (4) 31 (4)
Ever-use of HRT: 328 (19) 137 (20) 39 (28) 12 (28) 4 (15) 3 (12) 133 (18)
Hormone receptor status:
ER-positive 744 (44) 352 (51) 90 (64) 13 (30) 1 (4) 13 (52) 275 (37)
ER-negative 351 (21) 154 (22) 14 (10) 6 (14) 16 (59) 5 (20) 156 (21)
ER-unknown 581 (35) 189 (27) 37 (26) 24 (56) 10 (37) 7 (28) 314 (42)
PR-positive 611 (36) 294 (42) 70 (50) 10 (23) 2 (7) 9 (36) 226 (30)
PR-negative 446 (27) 196 (28) 32 (23) 9 (21) 15 (56) 9 (36) 185 (25)
PR-unknown 619 (37) 205 (30) 39 (27) 24 (56) 10 (37) 7 (28) 334 (45)
bc = breast cancer
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fathers with cancer with a daughter with lobular breast
cancer were prostate cancer (6%), leukemia (4%), lung
cancer (1%), lower gastrointestinal tract cancer (3%), sto-
mach cancer (2%) and sarcoma (2%). The fathers of lobu-
lar breast cancer patients were overrepresented in all
groups compared to the fathers of ductal breast cancer
patients, except lung cancer. No case of male breast can-
cer was present in these families (Table 5).
An increased probability to having a father diagnosed
with prostate cancer was found in lobular breast cancer
patients, OR 2.4 (CI 1.1-5.3). To determine whether this
association was dependent on age a cut off at 60 years old
was introduced. In patients diagnosed before age 60 the
effect remained, OR 2.9 (CI 1.1-7.8). Analysis on patients
diagnosed 60 years of age and older, the statistical signifi-
cance of the association was lost, OR 1.9 (CI 0.5-7.4). To
determine whether the association between lobular breast
cancer and the father having cancer was due to prostate
cancer alone, fathers prostate cancer was removed from
the analysis. The association between lobular breast cancer
patients and having a father diagnosed with cancer
remained, OR 1.9 (CI 1.2-2.8) (Table 6).
In the lobular breast cancer patient group, 41 of the
58 of the fathers diagnoses and age at diagnosis where
confirmed. The median age at cancer diagnosis for the
fathers of the lobular breast cancer patients was 70
years old. The median age of the father at their daugh-
ter’s birth was 32 years old. It does not necessarily
represent age at first child, since the patients diagnosed
with lobular breast cancer must not be the oldest child
(Table 7).
To eliminate the possibility that the paternal side had
an increase of both cancer diagnoses in general and/or
breast cancer in particular, compared to the maternal
side, both the parents of the father and the mother were
studied in all lobular breast cancer patients. On the
paternal side 5 grandfathers and 13 grandmothers were
diagnosed with cancer, and on the maternal side 4 grand-
fathers and 12 grandmothers were diagnosed with cancer.
There were 5 maternal and 4 paternal grandmothers
diagnosed with breast cancer. A binomial test was
Table 2 Breast cancer subtype in relation to parental cancer diagnosis status
a) Father with cancer, n = 297 Mother with cancer, n = 328
n OR 95% CI p-value OR 95% CI p-value
Ductal 630 0.95 0.74-1.12 0.71 1.13 1.01-1.65 0.04
Lobular 137 1.76 1.17-2.63 0.006 1.03 0.66-1.60 0.90
Tubular 43 0.84 0.37-1.93 0.69 0.41 0.16-1.08 0.07
Medullary 26 0.39 0.09-1.65 0.20 0.44 0.13-1.55 0.20
Mucinous 25 0.90 0.30-2.65 0.85 0.91 0.32-2.62 0.87
b) Father with cancer, n = 297 Mother with cancer, excluding breast cancer, n = 245
n OR 95% CI p-value OR 95% CI p-value
Ductal 629 0.95 0.73-1.23 0.70 1.30 0.99-1.71 0.06
Lobular 137 1.77 1.18-2.65 0.006 0.84 0.51-1.41 0.52
Tubular 43 0.85 0.37-1.93 0.69 0.52 0.18-1.48 0.22
Medullary 26 0.39 0.09-1.65 0.20 0.78 0.23-2.63 0.69
Mucinous 25 0.92 0.31-2.72 0.88 0.26 0.03-1.91 0.18
Logistic regression models with histopathologic type of breast cancer as dependent variable related to having a father and/or a mother diagnosed with cancer.
a, b) were both adjusted for age at diagnosis, breast cancer heredity, ever-use of HRT and number of children. N = 1661. b) was similar to a) but cases with a
mother diagnosed with breast cancer were excluded from the analysis. N = 1661. There was no interaction between having a father and a mother diagnosed
with cancer; b = 0.681, p-value = 0.428 (data not shown).
Table 3 Risk factors related to lobular breast cancer
All No family history of bc
OR 95% CI p-value OR 95% CI p-value
Father with cancer 2.17 1.37-3.46 0.001 2.20 1.22-3.94 0.008
ER-status 3.52 1.76-7.03 < 0.001 3.78 1.67-8.59 0.001
PR-status 0.87 0.52-1.46 0.61 0.82 0.45-1.51 0.53
Horizontal inheritance 1.36 0.58-3.20 0.48
Vertical inheritance 0.88 0.53-1.47 0.63
Binary logistic regression model with lobular breast cancer as dependent variable, adjusted for age at diagnosis. N = 1036 and 681, respectively. bc = breast
cancer.
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was noted (data not shown).
Discussion
Our data suggest a new familial pattern in patients with
lobular breast cancer, demonstrating an association
between lobular breast cancer and cancer in the father.
Non-BRCA1/2 high risk breast cancer families have pre-
viously been associated with prostate cancer reported by
Loman et al. [ 1 5 ] .T h es t u d yb yL o m a net al. was not
made with pure lobular breast cancer, rather breast can-
cer in general. Associations between breast cancer and
prostate cancer effects have been reported in three other
studies as well [16-18], however no subdivision based on
histopathologic breast cancer subtype was made. In a
s t u d yb yR a w a let al. [19] no association between pros-
tate cancer and breast cancer was found. Neither of pre-
vious studies did subdivide their data based on
histopathological types which could explain why they
did not identify an association similar to ours.
It is clear that the association between a father with
cancer and lobular breast cancer is not affected by a
mother diagnosed with breast cancer, since there was no
change in the results when removing cases with breast
cancer diagnoses. Also, no interaction between the father
and mother with cancer was found. Since the model was
adjusted for ever-use of HRT, which is associated with an
increased risk of lobular breast cancer [2], and number of
children the likelihood that the finding is dependent on
these factors seems unlikely. However, the power of the
study was small because of the small sample size. Adding
that to the fact that it is an exploratory study, the results
need to be validated in an independent cohort.
The median age at diagnosis of the fathers of the lobu-
lar breast cancer patient was close to the median age at
diagnosis for men in Sweden, which was approximately
75 years old in 2009 [20]. Several of the fathers were
born in the middle or late nineteenth century and if they
were diagnosed with cancer at an early age they were not
registered. These results are therefore biased due to the
fact that information regarding cancer diagnosis in those
fathers diagnosed at a younger age could not be con-
firmed since the Swedish tumor registry was not started
until 1958.
Our data indicates that different tumor types of tumors
in the father are associated with lobular breast cancer in
t h ed a u g h t e r .T h et h e o r yt h a tt h e r em i g h tb eag e n e t i c
cause is strengthened by the fact that it was the younger
lobular breast cancer patients that had an increased risk of
having a father with prostate cancer, compared to the
other histopathologic breast cancer subtypes. Genetically
caused breast cancer tends to present earlier than sporadic
ones [21]. However, the loss of statistical significance in
the older patient group could be due to the sample size,
which was smaller in the older patient group. It is impor-
tant to remember that the association between lobular
breast cancer and having a father diagnosed with cancer
remained significant even when removing cases with a
father diagnosed with prostate cancer. Indicating that this
phenomenon is not connected to prostate cancer exclu-
sively and that the remaining diagnoses that were more
common amongst fathers of lobular breast cancer patients,
such as leukemia, sarcoma and lower GI-tract cancer may
be involved as well. In some families, sarcoma and breast
cancer is associated with the Li-Fraumeni syndrome. How-
ever, none of our families fulfill the criteria for either Li-
Fraumeni, or Li-Fraumeni like syndrome. That together
with the age at onset of our patients strongly indicate that
this is not connected with the Li-Fraumeni syndrome, in
which the cancer usually presents at a much earlier age
[22,23]. Therefore, the task remains to determine if our
finding is due to chance or represents a new syndrome.
Table 5 Cancer diagnoses in fathers stratified based on
histological subtype of breast cancer
Ductal bc Lobular bc
Prostate cancer 4% 6%
Leukemia 2% 4%
Lung cancer 2% 1%
Stomach cancer 1% 2%
Lower GI-tract cancer 1% 3%
Sarcoma 0% 2%
Other cancer diagnoses 7% 9%
Comparisons of cancer diagnoses in father of patients diagnosed with ductal
and lobular breast cancer. Information regarding diagnosis was given by the
breast cancer patient at time of her breast cancer diagnosis. bc = breast
cancer
Table 4 Lobular breast cancer in relation to first degree relatives
All No breast cancer in 1
st degree relatives
OR 95% CI p-value OR 95% CI p-value
Father 1.84 1.23-2.74 0.003 1.83 1.23-2.74 0.003
Mother 0.98 0.65-1.49 0.93 0.98 0.65-1.49 0.93
Brother 1.05 0.52-2.09 0.90 1.05 0.52-2.09 0.90
Sister 1.20 0.73-1.96 0.47 1.20 0.73-1.96 0.47
Logistic regression model with lobular breast cancer as dependent variable in relation to first degree relatives diagnosed with cancer, adjusted for age at
diagnosis. N = 1642.
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and third degree relatives on the paternal or maternal
side of the lobular breast cancer cases indicating that
the association is not connected to an imbalance in
number of cancer diagnoses on the paternal side. It also
indicates that it may only be related to the father, or
inherited from the father.
There are several possible theories explaining this phe-
nomenon; one could be imprinting. In that case it could
mean that the gene or polymorphism was maternally
imprinted and therefore only the father’sa l l e l ew o u l db e
expressed, and predispose for cancer in men and breast
cancer in their daughters. A recent study by Kong et al.
[24] found a region at 11p15 with a paternal inheritance
associated with breast cancer, which further supports the
possibility of allelic imprinting or a peculiar inheritance
involving males with cancer and females developing
breast cancer. Another possibility could be copy number
variation which, when placed in a gene beneficial for can-
cer development could predispose for cancer in men and
breast cancer in women. A third possible explanation
could be that it is due to common recessive haplotypes.
Which in a heterozygote state predisposes for cancer in
men but not women, and in a homozygote state predis-
poses for breast cancer in women. A fourth explanation
could be that it is due to uniparental disomy (UPD)
where both alleles, in this case, would be inherited from
the father. However, the incidence of UPD has been esti-
mated to be 1/80 000 births [25], which makes this
hypothesis rather unlikely since we have several cases of
patients with a father with cancer and are nowhere near
a rate of 1/80 000.
Patients are referred to the Department of Oncology
from the Southern Health Care Region in a population
based setting. Since Skåne University Hospital, Lund is
responsible for radio- and chemotherapy in the southern
health care region of Sweden. The present clinical material
was slightly younger at diagnosis compared to the median
age at diagnosis in the southern health care region of Swe-
den. This is most likely because some older cases and
cases only operated without adjuvant therapy (stage I) may
not be referred to the Oncology clinic of Skåne University
Hospital, Lund. Overall we receive around 60% of all
breast cancer cases for therapy. Therefore our results may
not fully be applicable to stage I or older patients. Bias in
patient selection, except for the slightly younger popula-
tion, as well as chance, seems unlikely. The material was
collected under a long time period, reducing the possibility
that it was a certain branch of the population included.
The material was collected for research purposes, and the
questionnaire was filled out by the physician in a struc-
tured interview, reducing the possibilities for different
types of biases. We decided not to correct for multiple
testing since this is an exploratory study [26]. The findings
in the present study need to be validated in an indepen-
dent material.
Conclusion
Our study has identified a possible father-daughter
inheritance pattern in lobular breast cancer, independent
of previous family history of breast cancer. These findings
need to be validated in other materials in order to later
elucidate the possible mechanism behind the association.
Table 6 Cancer diagnoses in the father related to lobular and ductal breast cancer
Father with prostate cancer, N = 1676 Father with cancer, not prostate cancer, N = 1597
OR 95% CI p-value OR 95% CI p-value
Ductal cancer y/n 1.0 0.6-2.0 0.90 0.9 0.7-1.2 0.58
Lobular cancer y/n 2.4 1.1-5.3 0.003 1.8 1.2-2.8 0.006
Other cancers y/n 1.0 1.0
Father with prostate cancer, age at diagnosis > 60, N = 677 Father with prostate cancer, age at diagnosis < 60, N = 983
OR 95% CI p-value OR 95% CI p-value
Ductal cancer y/n 1.4 0.5-4.0 0.55 0.9 0.4-2.0 0.74
Lobular cancer y/n 1.9 0.5-7.4 0.34 2.9 1.1-7.8 0.003
Other cancers y/n 1.0 1.0
Logistic regression models with father diagnosed with cancer as the dependent variable. a) Relating prostate cancer in fathers to histopathologic subtype of
breast cancer, b) relating father diagnosed cancer, excluding cases with a father diagnosed with prostate cancer, to histopathologic subtype of breast cancer, c)
relating breast cancer patients younger than 60 years of age at diagnosis that have a father diagnosed with prostate cancer to histopathologic subtype of breast
cancer, and d) relating breast cancer patients diagnosed at age 60 and above With a father diagnosed with prostate cancer to histopathologic subtype of breast
cancer. a, b, c, d) were all adjusted for age at diagnosis.
Table 7 Descriptive
Family history of
breast cancer
All Yes No Prostate
Fathers age at daughter’s birth 32 32 33 31
Fathers age at cancer diagnosis 70 70 67 70
Daughter’s age at bc diagnosis 60 60 54 50
Description of the age of the father with a cancer diagnosis, or proband
(lobular breast cancer patients with a father diagnosed with cancer) at specific
events. Confirmation of the cancer diagnosis was possible in 41 of 58 the
fathers. bc = breast cancer.
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